Trendlines’ shares in BioSight were acquired by Arkin Bio Ventures Ltd. in June 2017.
BioSight develops advanced therapeutics to enable safe and effective treatment for life-threatening diseases and to improve the quality of life for patients with cancer and related diseases.
BioSight’s pipeline of targeted chemotherapy pro-drugs target cancer cells and release active chemotherapy drugs inside the cancer cells while significantly minimizing the toxicity associated with conventional chemotherapy treatments.
Astarabine™, the company’s lead proprietary product is in clinical stages for the treatment of leukemia.
Novel treatment for vertebral compression fractures
Preventing catheter-associated urinary tract infections (CAUTIs)
Wireless, wearable vital sign monitoring system
Cryotherapy for superficial bladder cancer
Endoscopic ultrasound fine needle biopsy system
Device to prevent preterm birth
Portable, automatic system for peritoneal dialysis